gastroenterology
IBS

New oral IBS drug improves symptoms

Phase III results for a new oral drug to treat patients with IBS and diarrhoea show a decrease in symptoms compared to placebo, but any benefit will need to be considered in the context of side effects and risks, the authors say. Marketed by Furiex Pharmaceuticals, an affiliate of Allergan, eluxadoline (Viberzi) works on the ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic